title: [2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer].
abstract: BACKGROUND
  The "Standards, Options and Recommendations" (SOR) project, started in 1993, is a collaboration between the Federation of French cancer centers (FNCLCC), the 20 French cancer centers, and specialists from French public universities, general hospitals and private clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients. The methodology is based on a literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery.
  
  
  OBJECTIVE
  To develop clinical practice guidelines for non small cell lung cancer patients according to the definitions of the Standards, Options and Recommendations project.
  
  
  METHODS
  Data were identified by searching Medline , web sites, and using the personal reference lists of members of the expert groups. Once the guidelines were defined, the document was submitted for review to independent reviewers.
  
  
  RESULTS
  This article presents the chapter "Prognosis significance of oncogenes and tumor suppressor genes" from the full report "Standards, Options and Recommendation for non small cell lung cancer" validated in August 2000. The main recommendations are: 1) No clear clinical prognostic value of oncogenes and tumor suppressor genes (p53, bcl-2, Ki-ras, c-erbB-2, Rb, p16) in non small cell lung cancer, can be established from the available evidences (standard, level of evidence C). 2) Prospective multicenter studies should be performed to assess prognostic significance of oncogenes and tumor suppressor genes in non small cell lung cancer.
authors.affiliation: FNCLCC, Standards, Options, Recommandations, 101, rue de Tolbiac, 75654 Paris Cedex 13, France.
authors.forename: Jeanne-Marie
authors.initials: JM
authors.lastname: Bréchot
authors.forename: Thierry
authors.initials: T
authors.lastname: Molina
authors.forename: Serge
authors.initials: S
authors.lastname: Theobald
authors.forename: Alain
authors.initials: A
authors.lastname: Depierre
authors.forename: Jean-Léon
authors.initials: JL
authors.lastname: Lagrange
authors.forename: Philippe
authors.initials: P
authors.lastname: Astoul
authors.forename: Pierre
authors.initials: P
authors.lastname: Baldeyrou
authors.forename: Etienne
authors.initials: E
authors.lastname: Bardet
authors.forename: Bernard
authors.initials: B
authors.lastname: Bazelly
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Breton
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Douillard
authors.forename: Michel
authors.initials: M
authors.lastname: Grivaux
authors.forename: Pascale
authors.initials: P
authors.lastname: Jacoulet
authors.forename: Antoine
authors.initials: A
authors.lastname: Khalil
authors.forename: Etienne
authors.initials: E
authors.lastname: Lemarié
authors.forename: Yves
authors.initials: Y
authors.lastname: Martinet
authors.forename: Gilbert
authors.initials: G
authors.lastname: Massard
authors.forename: Bernard
authors.initials: B
authors.lastname: Milleron
authors.forename: Denis
authors.initials: D
authors.lastname: Moro-Sibilot
authors.forename: Marianne
authors.initials: M
authors.lastname: Paesmans
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Pujol
authors.forename: Anne-Elisabeth
authors.initials: AE
authors.lastname: Quoix
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Ranfaing
authors.forename: Alain
authors.initials: A
authors.lastname: Rivière
authors.forename: Hélène
authors.initials: H
authors.lastname: Sancho-Garnier
authors.forename: Pierre-Jean
authors.initials: PJ
authors.lastname: Souquet
authors.forename: Dominique
authors.initials: D
authors.lastname: Spaeth
authors.forename: Anne
authors.initials: A
authors.lastname: Stcebner-Delbarre
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics / Q000378:metabolism; D005602:France; D015972:Gene Expression Regulation, Neoplastic; D016161:Genes, Retinoblastoma; D016147:Genes, Tumor Suppressor; D018734:Genes, erbB-2; D016158:Genes, p53; D011905:Genes, ras; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D009154:Mutation; D009857:Oncogenes; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism
chemical_list: D019941:Cyclin-Dependent Kinase Inhibitor p16; D019253:Proto-Oncogene Proteins c-bcl-2